Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

EGFRviii antibody (AA 1-50)

EGFRv3 Reactivity: Human WB, FACS, IF (cc), IF (p), ELISA, IHC (fro), IHC (p) Host: Rabbit Polyclonal unconjugated
Catalog No. ABIN742035
  • Target See all EGFRviii (EGFRv3) products
    EGFRviii (EGFRv3) (EGFR vIII (EGFRv3))
    Binding Specificity
    • 14
    • 3
    AA 1-50
    Reactivity
    Human
    Host
    • 17
    Rabbit
    Clonality
    • 17
    Polyclonal
    Conjugate
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This EGFRviii antibody is un-conjugated
    Application
    Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), ELISA, Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    Cross-Reactivity
    Chicken, Human, Mouse
    Purification
    Purified by Protein A.
    Immunogen
    KLH conjugated synthetic peptide derived from human EGFRvIII
    Isotype
    IgG
  • Application Notes
    WB 1:100-1000
    IHC-P 1:100-500
    IF(IHC-P) 1:50-200
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 μg/μL
    Buffer
    0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C,-20 °C
    Storage Comment
    Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
    Expiry Date
    12 months
  • Khelwatty, Essapen, Bagwan, Green, Seddon, Modjtahedi: "The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer." in: Oncotarget, Vol. 8, Issue 5, pp. 7666-7677, (2018) (PubMed).

    Wei, Cui, Zhou, Fang, Tan, Chen, Yang, Liu, Kang: "F25P preproinsulin abrogates the secretion of pro-growth factors from EGFRvIII cells and suppresses tumor growth in an EGFRvIII/wt heterogenic model." in: Cancer letters, Vol. 380, Issue 1, pp. 1-9, (2016) (PubMed).

    Wang, Kang, Wang-Gou, Huang, Feng, Li: "EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma." in: Cancer letters, Vol. 384, pp. 9-18, (2016) (PubMed).

    Liu, Han, Dong, Tan, Li, Zhao, Xie, Ju, Wang, Zhao, Zheng, Wang, Su, Fang, Fu, Jiang, Liu, Li, Kang, Ren: "EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis." in: Oncotarget, Vol. 7, Issue 4, pp. 4680-94, (2016) (PubMed).

    Wehrenberg-Klee, Redjal, Leece, Turker, Heidari, Shah, Mahmood: "PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance." in: American journal of nuclear medicine and molecular imaging, Vol. 5, Issue 4, pp. 379-89, (2015) (PubMed).

    Jørgensen, Bæk, Varming: "Potentials and capabilities of the Extracellular Vesicle (EV) Array." in: Journal of extracellular vesicles, Vol. 4, pp. 26048, (2015) (PubMed).

    Agnes, Broome, Wang, Verma, Lavik, Basilion: "An optical probe for noninvasive molecular imaging of orthotopic brain tumors overexpressing epidermal growth factor receptor." in: Molecular cancer therapeutics, Vol. 11, Issue 10, pp. 2202-11, (2012) (PubMed).

  • Target
    EGFRviii (EGFRv3) (EGFR vIII (EGFRv3))
    Abstract
    EGFRv3 Products
    Background

    Synonyms: EGFR vIII, EGFRvIII, Epidermal growth factor receptor variant type _, epidermal growth factor receptor isoform a variant, ERBB, HER1, ERBB1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, EGFR

    Background: Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Isoform 2 may act as an antagonist of EGF action.

    Gene ID
    1956
    UniProt
    Q59FL8
You are here:
Support